Healthcare Equipment and Supplies
Company Overview of Lumenis Ltd.
Lumenis Ltd., together with its subsidiaries, develops and commercializes energy-based medical systems for use in minimally invasive procedures worldwide. It operates through three segments: Surgical, Ophthalmic, and Aesthetic. The Surgical segment offers surgical laser systems and accessories used for urology/genitourinary and ENT to hospitals, outpatient clinics, ambulatory surgery centers, and medical practices. The Ophthalmic segment sells ophthalmology laser systems and accessories, such as laser links, slit lamp microscopes, laser indirect ophthalmoscopes, physician eye safety filters, surgical laser probes, and others to ophthalmic practices, outpatient clinics, and ophthalmology depa...
Yokneam Industrial Park
PO Box No. 240
Founded in 1991
Key Executives for Lumenis Ltd.
Senior VP and Regional President - APAC & Japan
Vice President and Regional President of Japan
VP & Regional President of Americas
Compensation as of Fiscal Year 2017.
Lumenis Ltd. Key Developments
Lumenis Ltd. to Highlight the Positive Impact of FiberLase™ CO2 Laser Treatment for Ovarian Endometrioma on Ovarian Reserve
Oct 18 17
Lumenis Ltd. announced that it will share new clinical data on its CO2 laser-based FiberLase™ for minimally-invasive treatment of endometriosis at the European Society for Gynecological Endoscopy (ESGE) 26th Annual Congress, October 18- 21 at the Sueno Hotel Belek & Convention Center in Antalya, Turkey. Endometriosis is a disease that affects roughly 10% of the world's female population. While the etiology of the disease is still unclear, treatment options exist and vary between symptomatic ease, hormonal supplements and hysterectomy when fertility is no longer of concern. Approximately 85% of endometriosis patients are diagnosed with ovarian endometriosis; these cases require delicate and precise treatment options to preserve fertility. Lumenis has collaborated with surgeons worldwide to develop an advanced surgical CO2 FiberLase™ laser procedure, which has been demonstrated to remove endometriosis lesions very delicately and precisely without harming the ovarian reserve. Recent studies show the treatment results in fast recovery time, less inflammation and pain, low risk of infection and low rate of side effects such as surgery-related adhesions. Patients experience immediate improvement in their quality of life, higher rates of fertility preservation and lower disease recurrence rates compared to RF technology. At the ESGE Annual Congress, Lumenis will highlight its innovations in treating endometriosis, including the advanced surgical CO2 lasers, UltraPulse® DUO and AcuPulse™ DUO. These laser systems utilize both Free Beam laser delivery and the flexible FiberLase™ fiber, designed to operate precisely around delicate pelvic anatomy with minimal thermal damage while keeping healthy tissue intact, significantly improving symptoms and quality of life while helping to preserve and protect fertility.
Lumenis Ltd. Announces Launch of New Moses™ Holmium Technology During 112th American Urological Association Annual Meeting in Boston
May 12 17
Lumenis Ltd. announced the launch of its new Moses™ Holmium technology during the 112th American Urological Association (AUA) annual meeting in Boston. The AUA launch of Moses follows a successful introduction of the technology during the last European Association of Urologists (EAU) annual congress in London, where hundreds of physicians had a firsthand experience of the Moses technology stressing its truly innovative nature and potential to revolutionize the world of holmium laser lithotripsy. Through a proprietary combination of holmium laser systems and fibers, Moses optimizes laser energy transmission to increase stone ablation volume while reducing dependency on the working distance between the fiber and stone. Further, the unique Moses pulse modulation reduces stone retropulsion and, in-turn, stone migration, leading to a more efficient treatment and greater physician control over the procedure. The Moses tailored premium fiber range of 200, 365, and 550 D/F/L is designed for optimal energy transmission and durability. Additionally, the Moses 200 D/F/L fiber allows surgeons to treat stones in difficult-to-reach locations, and enables smooth initial fiber insertion through a deflected scope. The innovative Moses Holmium technology was acknowledged by the AUA’s scientific committee as it was chosen to be presented during the AUA Stone Disease Surgical Therapy podium session. This session will include the pre-clinical study done by Prof. Mostafa Elhilali of McGill University Health Center Department of Urology in Montreal, Canada, who passed away two weeks ago.
Lumenis Ltd. Introduces OtoLase
Sep 16 16
Lumenis Ltd. announced the introduction of OtoLase™, the new otology designated enhancement for the AcuPulse™ family of products. Specifically designed for enhanced precision and ease of use in middle ear surgery, the innovative OtoLase will be showcased at the American Academy of Otolaryngology " Head and Neck Surgery Foundation (AAO-HNSF) Annual meeting 2016, being held in San Diego on September 18-21, 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|